Jorge B.
- Country
- Spain
- Department
- Medical Oncology
Research Overview
Data & Insights
Has run more than one trial at 0 of 19 partner sites.
Specializations
Advanced Solid Tumors & Biomarker‑Driven Oncology
Focus on late‑stage solid tumors that require molecular stratification for therapeutic selection.
- KRAS G12C‑mutated cancers
- HER2‑positive breast and gastric malignancies
- PD‑L1‑selected non‑small cell lung cancer
- MSI‑high / dMMR colorectal and endometrial cancers
- Tumor mutational burden‑high (TMB‑H) disease
Clinical programs integrate targeted agents with standard regimens to address resistance mechanisms.
Hematologic Malignancies
Investigation of therapeutic options for aggressive and relapsed blood cancers.
- Acute myeloid leukemia (AML)
- Chronic lymphocytic leukemia (CLL)
- Multiple myeloma (MM)
- Diffuse large B‑cell lymphoma (DLBCL)
- Myelodysplastic syndromes (MDS)
Emphasis on novel agents, combination strategies, and maintenance therapies.
Immunotherapy & Checkpoint Inhibition Strategies
Development and evaluation of immune‑modulating treatments across tumor types.
- Anti‑PD‑L1 antibody combinations
- Anti‑TIGIT agents
- CAR‑T cell platforms for B‑cell malignancies
- Immune‑checkpoint blockade in melanoma and renal cell carcinoma
- Biomarker‑guided patient selection
Trials assess efficacy, safety, and mechanistic profiles of immune‑based regimens.
Rare and Molecularly Defined Cancers
Targeted exploration of low‑prevalence malignancies with distinct genetic drivers.
- Neuroendocrine tumors of the lung and gastrointestinal tract
- Mesothelioma with BAP1 alterations
- Cholangiocarcinoma harboring IDH mutations
- RET‑fusion positive non‑small cell lung cancer
- ALK‑rearranged tumors
Precision medicine approaches aim to match targeted inhibitors to actionable mutations.
Oncology‑Related Supportive Care & Comorbidities
Addressing treatment‑related complications and concurrent disease states.
- Management of cancer‑associated thrombosis
- Renal impairment in patients receiving nephrotoxic agents
- Cardiovascular risk mitigation in oncology populations
- Infection prophylaxis for immunocompromised hosts
- Quality‑of‑life assessment in advanced disease
Integrative protocols support optimal outcomes alongside anticancer therapy.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.